Enliven Therapeutics, Inc.
6200 Lookout Road
Boulder, Colorado 80301
June 29, 2023
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
|
|
Re: |
Enliven Therapeutics, Inc. | ||
| Registration Statement on Form S-3 | ||||
| Filed June 23, 2023 | ||||
| File No. 333-272909 |
| Acceleration Request | ||||||
| Requested Date: | July 3, 2023 | |||||
| Requested Time: | 4:00 p.m. Eastern Time, | |||||
| or as soon thereafter as practicable |
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Enliven Therapeutics, Inc. (the “Company”) hereby respectfully requests that the above-referenced Registration Statement on Form S-3 (File No. 333-272909) (the “Registration Statement”) be declared effective at the “Requested Date” and “Requested Time” set forth above or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission.
Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Wilson Sonsini Goodrich & Rosati, Professional Corporation, by calling Jennifer Knapp at (650) 849-3041.
Please direct any questions or comments regarding this acceleration request to Jennifer Knapp at (650) 849-3041.
[Signature Page Follows]
| Very truly yours, |
| Enliven Therapeutics, Inc. |
| /s/ Samuel Kintz |
| Samuel Kintz |
| President and Chief Executive Officer |
| cc: | Tony Jeffries, Wilson Sonsini Goodrich & Rosati, Professional Corporation |
Jennifer Knapp, Wilson Sonsini Goodrich & Rosati, Professional Corporation
[Signature Page to the Company’s Acceleration Request]